Home > Healthcare > Pharmaceuticals > Vaccines > Vaccine Adjuvants Market

Vaccine Adjuvants Market Trends

Report ID: GMI12365
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Vaccine Adjuvants Market Trends

The significance of adjuvant research has grown considerably due to the limited immunogenicity of new vaccine antigens. The National Institutes of Health (NIH) has stressed the importance of developing adjuvants to improve vaccine efficacy, especially for populations with weakened immune systems, such as the elderly and immunocompromised individuals. This focus on research is expected to drive advancements in adjuvant technology.
Furthermore, the increasing utilization of recombinant and synthetic vaccines is anticipated to accelerate the growth of the adjuvant market in the upcoming years.
The WHO’s Global Vaccine Action Plan highlights the necessity of developing new and improved vaccines, including those utilizing recombinant technology. As these advanced vaccines frequently require adjuvants to enhance their effectiveness, their rising adoption is likely to further fuel the demand for adjuvants in vaccine formulations.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global vaccine adjuvants industry was valued at approximately USD 1.3 billion in 2024 and is estimated to grow at a 6.5% CAGR from 2025 to 2034, driven by the increasing need for vaccines with enhanced efficacy.

The particulate adjuvants segment accounted for 35.4% of the market revenue share in 2024 due to their ability to significantly boost the immune response, making vaccines more effective.

The U.S. vaccine adjuvants market is projected to reach USD 927.5 million by 2034, fueled by substantial government investments in vaccine research and public health initiatives.

Key players in the vaccine adjuvants sector include Agenus, Allergy Therapeutics, Aurorium, Brenntag Biosector, Croda International, CSL Limited, Dynavax Technologies Corporation, EuBiologics, GSK plc, Merck KGaA, Novavax, and OZ Biosciences.